AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Article Link
Collect
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

An exploratory study of the dose correlation between point B and metastatic lymph nodes in three-dimensional high-dose-rate brachytherapy for cervical cancer

Dongming YangYuhua Gao( )
Department of Radiotherapy, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, Shenyang, China
Show Author Information

Abstract

Objective

To determine the dose correlation between point B and metastatic lymph nodes in cervical cancer treated with three-dimensional (3D) high-dose-rate (HDR) brachytherapy.

Methods

A retrospective study was conducted involving 30 cervical cancer patients with lymph node metastases who completed 3D HDR brachytherapy at Liaoning Cancer Hospital and Institute from May 2019 to November 2020. Brachytherapy was performed with a Fletcher applicator at a prescribed dose of 28 Gy/4 f. Computed tomography images of the external irradiation target were fused with delineated images of the brachytherapy target on the MIM system. The minimum dose received by 90% of the volume (D90) was read on the MIM system for all metastatic lymph nodes and the point B dose was read for the brachytherapy target area. In total, 78 metastatic lymph nodes from 30 patients with cervical cancer were included in this study, including para-aortic, common iliac, external iliac, internal iliac, obturator, and inguinal lymph nodes. Paired t-tests and Pearson correlation coefficient analyses were performed to examine the difference in the equivalent dose between each group of metastatic lymph nodes and point B.

Results

The mean equivalent point B dose was 6.69 ± 1.08 Gy. There were significant differences in dose between point B and the para-aortic, common iliac, external iliac, internal iliac, and inguinal lymph nodes (p < 0.05), with a weak positive correlation (r < 0.4). There was no statistically significant difference in dose between obturator lymph nodes and point B (p = 0.3999), with a positive correlation (r = 0.65).

Conclusion

3D HDR brachytherapy contributed significantly to pelvic lymph node doses in cervical cancer patients with lymph node metastasis, but less to para-aortic and inguinal lymph node doses. The dose at point B grossly overestimated the mean dose to pelvic lymph nodes; only the dose to obturator lymph nodes was similar to that of point B, with a slightly positive correlation.

References

1

Kidd EA, Siegel BA, Dehdashti F, et al. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol. 2010; 28(12): 2108-2113.

2

Pedone Anchora L, Carbone V, Gallotta V, et al. Should the number of metastatic pelvic lymph nodes be integrated into the 2018 Figo staging classification of early stage cervical cancer. Cancers (Basel). 2020; 12(6): 1552.

3

Nica A, Gien LT, Ferguson SE, Covens A. Does small volume metastatic lymph node disease affect long-term prognosis in early cervical cancer? Int J Gynecol Cancer. 2020; 30(3): 285-290.

4

Zeng J, Qu P, Hu Y, et al. Clinicopathological risk factors in the light of the revised 2018 International Federation of Gynecology and Obstetrics staging system for early cervical cancer with staging IB: a single center retrospective study. Medicine (Baltimore). 2020; 99(16): e19714.

5

Kim JK, Kim KA, Park BW, Kim N, Cho KS. Feasibility of diffusion-weighted imaging in the differentiation of metastatic from nonmetastatic lymph nodes: early experience [published correction appears in J Magn Reson Imaging. 2009 May; 29(5): 1242. J Magn Reson Imaging. 2008; 28(3): 714-719.

6

Glavak C, Toller G, Volgyi Z, et al. PO-0814: initial experiences with coverage probability based nodal SIB RT in cervical cancer. Radiother Oncol. 2018; 127: S424-S425.

7

Singh DP, Bylund KC, Matloubieh A, et al. Is there a subset of patients with recurrent cancer in the vagina who are not candidates for interstitial brachytherapy that can be treated with multichannel vaginal brachytherapy using graphic optimization. J Contemp Brachyther. 2015; 7(2): 135-141.

8

Schröder C, Stiefel I, Tanadini-Lang S, et al. Re-irradiation in the thorax – an analysis of efficacy and safety based on accumulated EQD2 doses. Radiother Oncol. 2020; 152: 56-62.

9

Snyder JE, Willett AB, Sun W, Kim Y. Is SBRT boost feasible for PET positive lymph nodes for cervical cancer? Evaluation using tumor control probability and QUANTEC criteria. Pract Radiat Oncol. 2019; 9(2): e156-e163.

10

Baak M, Koopman R, Snoek H, et al. A new correlation coefficient between categorical, ordinal and interval variables with Pearson characteristics. Comput Stat Data Anal. 2020; 152: 107043.

11

Basu B, Basu S, Chakraborti B, et al. A comparison of dose distribution from Manchester-style and Fletcher-style intracavitary brachytherapy applicator systems in cervical cancer. J Contemp Brachyther. 2012; 4(4): 213-218.

12

van den Bos W, Beriwal S, Velema L, de Leeuw AA, Nomden CN, Jürgenliemk-Schulz IM. Image guided adaptive brachytherapy for cervical cancer: dose contribution to involved pelvic nodes in two cancer centers. J Contemp Brachyther. 2014; 6(1): 21-27.

13

McKeever MR, Hwang L, Barclay J, et al. A ready reference for estimating dose to pelvic node metastases from high-dose-rate brachytherapy in cervical cancer. Brachytherapy. 2014; 13: S64-S65.

14

Lee YC, Rash DL, Stern RL, Mathai M. Variation in high-dose-rate brachytherapy dose contribution among pelvic lymph nodes groups in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2014; 90(1): S478.

15

Bacorro W, Dumas I, Levy A, et al. Contribution of image-guided adaptive brachytherapy to pelvic nodes treatment in locally advanced cervical cancer. Brachytherapy. 2017; 16(2): 366-372.

16

Matsukawa H, Sasaki T, Hirayama R, Hirose TA, Fukunaga JI. Assessment of the anatomical position of point B and the relationship between point B dose and the dose delivered to pelvic lymph nodes in CT-based high-dose-rate brachytherapy for uterine cervical cancer. J Contemp Brachyther. 2019; 11(2): 137-145.

17

Lee LJ, Sadow CA, Russell A, Viswanathan AN. Correlation of point B and lymph node dose in 3D-planned high-dose-rate cervical cancer brachytherapy. Int J Radiat Oncol Biol Phys. 2009; 75(3): 803-809.

18

Mohamed SM, Aagaard T, Fokdal LU, Pedersen EM, Lindegaard JC, Tanderup K. Assessment of radiation doses to the para-aortic, pelvic, and inguinal lymph nodes delivered by image-guided adaptive brachytherapy in locally advanced cervical cancer. Brachytherapy. 2015; 14(1): 56-61.

19

Rangarajan R, Subramanian S, Gopalakrishnan K, Jothi V, Krishnamurthy K. Dose to pelvic lymph nodes in image based high dose rate brachytherapy of carcinoma cervix. Rep Pract Oncol Radiother. 2019; 24(1): 80-85.

Precision Radiation Oncology
Pages 209-215
Cite this article:
Yang D, Gao Y. An exploratory study of the dose correlation between point B and metastatic lymph nodes in three-dimensional high-dose-rate brachytherapy for cervical cancer. Precision Radiation Oncology, 2022, 6(3): 209-215. https://doi.org/10.1002/pro6.1168

460

Views

0

Crossref

0

Scopus

Altmetrics

Received: 19 April 2022
Revised: 04 June 2022
Accepted: 29 June 2022
Published: 10 August 2022
© 2022 The Authors. Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Return